1
|
Reif S, Schubert S, Stiefel J, Husri F, Fischlein T, Pauschinger M, Klucken J. Supporting patients with heart failure with digital therapeutics-A pilot study in Germany. Digit Health 2022; 8:20552076221143899. [PMID: 36583086 PMCID: PMC9793018 DOI: 10.1177/20552076221143899] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Accepted: 11/18/2022] [Indexed: 12/24/2022] Open
Abstract
Objective Continuous monitoring and targeted behavioral interventions have been shown to improve health status and quality of life for heart failure patients. Digital therapeutics offer the possibility to make more frequent monitoring and targeted behavioral interventions available for more people. Methods We conduct a pilot study with 71 patients who were given a smartphone app and wearables for a 3-month period. Clinical indicators as well as patient-reported outcomes were collected at entry and exit examinations. Results The New York Heart Association class remained stable or improved. Most quantitative outcome measures improved (6-minute walk test distance + 21 m, Kansas City Cardiomyopathy Questionnaire summary score + 6.0 points, European Heard Failure Self-care Behavior Scale summary score + 6.6 points, correct answers in the Atlanta Heart Failure Knowledge Test + 2.1), although the changes were mainly not significantly different from zero. There was no change in EQ-5D weight and 9-item Shared Decision-Making Questionnaire summary score. Conclusions This before-after comparison shows that an app-based intervention can work as a digital therapeutic for heart failure patients.
Collapse
Affiliation(s)
- S. Reif
- ZEW – Leibniz Centre for European Economic Research, Mannheim,
Germany,S. Reif, ZEW - Leibniz Centre for European
Economic Research, L7 1, 68161 Mannheim, Germany.
| | - S. Schubert
- ZEW – Leibniz Centre for European Economic Research, Mannheim,
Germany,FAU University Erlangen-Nurnberg, Nürnberg, Germany
| | - J. Stiefel
- dmac – Medical Valley Digital Health Application Center, Bamberg,
Germany
| | - F. Husri
- Department of Cardiac Surgery, Klinikum Nürnberg (Cardiovascular
Center), Paracelsus Medical University, Nürnberg, Germany
| | - T. Fischlein
- Department of Cardiac Surgery, Klinikum Nürnberg (Cardiovascular
Center), Paracelsus Medical University, Nürnberg, Germany
| | - M. Pauschinger
- Department of Cardiology, Klinikum Nürnberg (Cardiovascular Center),
Paracelsus Medical University, Nürnberg, Germany
| | - J. Klucken
- Digital Medicine Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg,Medicine Group, Department of Precision Health, Luxembourg Institute
of Health (LIH), Strassen, Luxembourg,Digital Medicine Group, Centre Hospitalier de Luxembourg (CHL),
Luxembourg
| |
Collapse
|
2
|
Raccagni C, Goebel G, Gaßner H, Granata R, Ndayisaba JP, Seebacher B, Schoenherr G, Mitterhuber J, Hendriks P, Kaindlstorfer C, Eschlboeck S, Fanciulli A, Krismer F, Seppi K, Poewe W, Bloem BR, Klucken J, Wenning GK. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. Parkinsonism Relat Disord 2019; 67:60-65. [PMID: 31621609 DOI: 10.1016/j.parkreldis.2019.09.026] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/26/2019] [Accepted: 09/23/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND AND OBJECTIVES Gait impairment and reduced mobility are disabling symptoms of multiple system atrophy. While physiotherapy is increasingly recognized as a valuable supplement to pharmacotherapy for patients with Parkinson's disease, data on the efficacy of physiotherapy for multiple system atrophy are lacking. This study aimed to explore the feasibility of two consecutive exercise-based interventions in patients with multiple system atrophy. SUBJECTS AND METHODS We included 10 patients with the parkinsonian variant of multiple system atrophy and 10 patients with Parkinson's disease, matched for gender and Hoehn & Yahr stage (≤3). Interventions consisted of a five-day inpatient physiotherapy program followed by a five-week unsupervised home-based exercise program. Outcomes included instrumented gait analysis, patient questionnaires, clinical rating scales and physical tests. Patients were examined at baseline, after the first inpatient treatment and again after the home-based intervention. Additionally, a structured telephone interview was performed immediately after the second intervention period. RESULTS Both patient groups exhibited a similar improvement of gait after the interventions, as measured by instrumented gait analysis. These effects reached their maximum level after inpatient physiotherapy and remained stable following the home-based exercise program. Patient questionnaires also showed improvements after the interventions, but motor clinical rating scales did not. CONCLUSION Our pilot results suggest that a short-term bout of physiotherapy is feasible, safe and improves gait performance in patients with multiple system atrophy. This highlights the potential of physiotherapy for this disabling condition where pharmacotherapy typically achieves poor effects. The present findings warrant a larger controlled study.
Collapse
Affiliation(s)
- C Raccagni
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - G Goebel
- Department of Medical Statistics, Informatics and Health Economics, Innsbruck University, Innsbruck, Austria
| | - H Gaßner
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University, Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Roberta Granata
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | | | - Barbara Seebacher
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Gudrun Schoenherr
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Jakob Mitterhuber
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Pascalle Hendriks
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | | | - Sabine Eschlboeck
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | | | - Florian Krismer
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Klaus Seppi
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Werner Poewe
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Bastiaan R Bloem
- Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, the Netherlands
| | - J Klucken
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University, Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Gregor K Wenning
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
| |
Collapse
|
3
|
Pasluosta C, Hannink J, Gaßner H, Von Tscharner V, Winkler J, Klucken J, Eskofier B. Motor output complexity in Parkinson’s disease during quiet standing and walking: Analysis of short-term correlations using the entropic half-life. Hum Mov Sci 2018; 58:185-194. [DOI: 10.1016/j.humov.2018.02.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Revised: 02/08/2018] [Accepted: 02/08/2018] [Indexed: 11/25/2022]
|
4
|
Marxreiter F, Gassner H, Barth J, Thun C, Volc D, Schlachetzki J, Winkler J, Eskofier B, Klucken J. EP 96. Sensor based gait analysis application for apomorphine titration. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2016.05.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Maetzler W, Krüger R, Müller T, Oertel W, Urban P, Warnecke T, Klucken J. [Wearable Technique for the Assessment of Parkinson Symptoms: What's the Future?]. Fortschr Neurol Psychiatr 2016; 84 Suppl 1:S48-51. [PMID: 27276073 DOI: 10.1055/s-0042-102786] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Parkinson's disease (PD) is a multisystem disorder with a plethora of symptoms affecting the quality of life of patients in the home environment. Due to the rapid development of wearable technique in the health and fitness sector, an increasing number of such wearable devices are available to complement diagnostic strategies of PD symptoms not only in the clinical but also in the home environment. This development has clear advantages over clinical evaluation, as the latter is relatively subjective, time-consuming and costly, and provides only a snapshot of the condition. First results about the use of such technology for the assessment of PD symptoms (including bradykinesia, dyskinesia, tremor, daily activity and sleep behavior) in the home environment are promising. They suggest that these techniques can provide complementary information about the symptoms of PD patients, and have the potential to be included in future diagnostic workup concepts of routine care in PD. The use of such technique provides also the opportunity to more actively include patients into medical decision-making processes.
Collapse
Affiliation(s)
- W Maetzler
- Neurologie mit Schwerpunkt Neurodegeneration und Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen, Tübingen
| | - R Krüger
- Neurologie mit Schwerpunkt Neurodegeneration und Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen, Tübingen
| | - T Müller
- Klinik für Neurologie, St. Joseph Krankenhaus Berlin-Weißensee, Berlin
| | - W Oertel
- Klinik für Neurologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Marburg
| | - P Urban
- Abteilung für Neurologie, Asklepios Klinik Barmbek, Hamburg
| | - T Warnecke
- Department für Neurologie, Universitätsklinikum Münster, Münster
| | - J Klucken
- Molekulare Neurologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen
| |
Collapse
|
6
|
Klucken J, Friedl KE, Eskofier BM, Hausdorff JM. Guest Editorial: Enabling Technologies for Parkinson's Disease Management. IEEE J Biomed Health Inform 2015; 19:1775-1776. [PMID: 26866073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
7
|
Klucken J, Friedl KE, Eskofier BM, Hausdorff JM. Guest Editorial: Enabling Technologies for Parkinson's Disease Management. IEEE J Biomed Health Inform 2015; 19:1775-1776. [PMID: 26866144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
8
|
Klucken J, Friedl KE, Eskofier BM, Hausdorf JM. Guest Editorial: Enabling Technologies for Parkinson's Disease Management. IEEE J Biomed Health Inform 2015. [DOI: 10.1109/jbhi.2015.2488158] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
Mrochen A, Marxreiter F, Kohl Z, Schlachetzki J, Renner B, Schenk T, Winkler J, Klucken J. From sweet to sweat: Hedonic olfactory range is impaired in Parkinson's disease. Parkinsonism Relat Disord 2015; 22:9-14. [PMID: 26627940 DOI: 10.1016/j.parkreldis.2015.09.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2015] [Revised: 08/15/2015] [Accepted: 09/17/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Olfactory dysfunction and neuropsychological symptoms like depression and anhedonia are common non-motor symptoms in Parkinson's disease (PD). The assessment of both functional domains includes clinical examination, olfactory testing, and standardized questionnaires. While olfaction is readily assessed by functional tests, the distinction of anhedonia as a separate symptom from other depressive symptoms is challenging. Thus, a test focusing on the assessment of hedonic olfaction may be helpful in the assessment of neuropsychological symptoms in PD. METHODS We examined anhedonia by evaluating the perception of pleasantness of odors in PD patients (n = 57) and healthy controls (n = 46). Pleasantness of odors was registered on a visual 9-point scale. For the assessment of anhedonia we used the Snaith-Hamilton-Pleasure-Scale (SHAPS). Depression was evaluated with the Zung Self-Rating Depression Scale and the Beck Depression Inventory II. RESULTS PD patients showed a substantial reduction in hedonic olfaction compared to controls (hedonic score: 1.5 vs. 2.2). Hyposmia, one of the most prevalent non-motor symptoms in PD, was a confounding factor. However, even normosmic PD patients showed a reduced hedonic olfaction compared to controls (hedonic score: 1.6 vs. 2.2). Furthermore, we observed a correlation between hedonic olfaction and the SHAPS-score for PD patients even though positive SHAPS-rating was observed in 9% of PD patients only, while no correlation to depression was present. CONCLUSION These findings suggest that reduced hedonic olfaction might be an additional neuropsychological feature, probably giving insights into changes in hedonic tone complementary to hyposmia and depression in PD.
Collapse
Affiliation(s)
- A Mrochen
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
| | - F Marxreiter
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany; Department of Neurology, University Hospital Erlangen, FAU, Schwabachanlage 6, 91054 Erlangen, Germany
| | - Z Kohl
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
| | - J Schlachetzki
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
| | - B Renner
- Department of Experimental and Clinical Pharmacology, FAU, Krankenhausstr. 9, 91054 Erlangen, Germany
| | - T Schenk
- Department of Neurology, University Hospital Erlangen, FAU, Schwabachanlage 6, 91054 Erlangen, Germany; Clinical Neuropsychology, Department of Psychology, Ludwig-Maximilians-University Munich, Leopoldstr. 13, 80802 Munich, Germany
| | - J Winkler
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
| | - J Klucken
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.
| |
Collapse
|
10
|
Vogelgsang J, Wiltfang J, Masliah E, Winkler J, Klucken J. Dopaminergic stimulation in a transgenic model of neurodegeneration restores decreased proliferation and viability in subventricular zone derived adult neural precursor cells. Pharmacopsychiatry 2015. [DOI: 10.1055/s-0035-1558039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Vogelgsang J, Wiltfang J, Masliah E, Winkler J, Klucken J. Dopaminergic stimulation in a transgenic model of neurodegeneration restores decreased proliferation and viability in subventricular zone derived adult neural precursor cells. Pharmacopsychiatry 2015. [DOI: 10.1055/s-0035-1558001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Klucken J, Herting B, Hilker R, Schulz J, Vieregge P, Woitalla D, Wolz M, Reichmann H. Parkinson-Syndrom(e) - Neue Konzepte für eine sich ausbreitende Erkrankung? Akt Neurol 2013. [DOI: 10.1055/s-0033-1349432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- J. Klucken
- Molekulare Neurologie, Universitätsklinikum Erlangen
| | - B. Herting
- Klinik für Neurologie und Gerontoneurologie, Diakonie-Klinikum Schwäbisch Hall
| | - R. Hilker
- Klinik für Neurologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt
| | - J. Schulz
- Neurologische Klinik, Universitätsklinikum der RWTH Aachen
| | - P. Vieregge
- Klinik für Neurologie, Klinikum Lippe-Lemgo GmbH
| | - D. Woitalla
- Neurologische Klinik, Universitätsklinikum der Ruhr-Universität Bochum
| | - M. Wolz
- Klinik für Neurologie, Elblandklinikum Meißen
| | - H. Reichmann
- Klinik und Poliklinik für Neurologie, Carl Gustav Carus Universität Dresden
| |
Collapse
|
13
|
Bollheimer LC, Volkert D, Bertsch T, Bauer J, Klucken J, Sieber CC, Büttner R. [Translational research in geriatrics? A plea based on current biomedical key publications]. Z Gerontol Geriatr 2012; 46:569-75. [PMID: 23242336 DOI: 10.1007/s00391-012-0414-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Contemporary geriatric research focuses mainly on observational clinical studies and epidemiological surveys and the translation of basic scientific results from biogerontology into a clinical context is often neglected. Following a definition of translational research the article gives an overview of recent key publications in experimental biogerontology with a special emphasis on their relevance for clinical geriatrics. The topics dealt with include age-induced loss of skeletal muscle (sarcopenia), the aging immune system (immunosenescence) and neurodegenerative disorders (Alzheimer's and Parkinson's disease).
Collapse
Affiliation(s)
- L C Bollheimer
- Institut für Biomedizin des Alterns, Friedrich-Alexander-Universität Erlangen-Nürnberg, Heimerichstr. 58, 90419, Nürnberg, Deutschland.
| | | | | | | | | | | | | |
Collapse
|
14
|
Klucken J, Barth J, Maertens K, Eskofier B, Kugler P, Steidl R, Hornegger J, Winkler J. [Mobile biosensor-based gait analysis: a diagnostic and therapeutic tool in Parkinson's disease]. Nervenarzt 2012; 82:1604-11. [PMID: 21748456 DOI: 10.1007/s00115-011-3329-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Parkinson's disease (PD) is characterized by progressive motor and non-motor symptoms, leading to distinct diagnostic and therapeutic challenges in all stages of the disease. This study investigated a mobile biosensor-based gait analysis system for patients in early and intermediate stages of PD compared to controls. Subjects wearing a motion sensor-equipped shoe performed a standardized gait exercise. Accelerometer- and gyroscope-based signals were analysed using a complex set of pattern recognition algorithms. The analysis was able (1) to distinguish between PD patients and controls, (2) to identify patients at an early stage of the disease and (3) to distinguish between early and intermediate stage patients. Thus, using this mobile biosensor-based analysis system we were able to obtain objective classifications of gait characteristics in PD. Future studies will show that mobile biosensor-based movement detection technology will support identification of early PD stages and allow objective characterization of motor fluctuations in advanced stages of the disease. This will provide an important and supportive tool for patients, caregivers and therapists.
Collapse
Affiliation(s)
- J Klucken
- Abteilung für Molekulare Neurologie und Spezialambulanz für Bewegungsstörungen in der Neurologischen Klinik, Universitätsklinikum Erlangen, Schwabachanlage 6, 91054 Erlangen, Deutschland.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Walter U, Klucken J, Benecke R, Winkler J. Hirnsonografie, Riechtestung und motorische Testverfahren in der Frühdiagnose des idiopathischen Parkinson-Syndroms. Akt Neurol 2012. [DOI: 10.1055/s-0031-1301298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- U. Walter
- Klinik und Poliklinik für Neurologie, Universität Rostock
| | - J. Klucken
- Abteilung für Molekulare Neurologie, Universitätsklinikum Erlangen
| | - R. Benecke
- Klinik und Poliklinik für Neurologie, Universität Rostock
| | - J. Winkler
- Abteilung für Molekulare Neurologie, Universitätsklinikum Erlangen
| |
Collapse
|
16
|
Gerlach M, Baas H, Jost W, Klucken J, Riederer P. Nutzen von Pharmakokinetik- und Pharmakogenetik-Wissen für die Parkinson-Therapie. Akt Neurol 2011. [DOI: 10.1055/s-0032-1304733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- M. Gerlach
- Universitätsklinikum für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg
| | - H. Baas
- Klinik für Neurologie, Klinikum Hanau
| | - W. Jost
- Deutsche Klinik für Diagnostik, Wiesbaden
| | - J. Klucken
- Abteilung für Molekulare Neurologie, Universitätsklinikum Erlangen
| | - P. Riederer
- Universitätsklinikum für Psychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg
| |
Collapse
|
17
|
Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost W. Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen? Fortschr Neurol Psychiatr 2010; 78 Suppl 1:S31-3. [DOI: 10.1055/s-0029-1245169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Klucken J, Winkler J. Autophagy und α-Synucleinaggregation beim M. Parkinson. Akt Neurol 2009. [DOI: 10.1055/s-0029-1238881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Klucken J, Winner B, Bogdahn U, Winkler J. Alpha-Synuclein Aggregation, Oligomerisierung und Toxizität. Akt Neurol 2008. [DOI: 10.1055/s-0028-1086808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Klucken J, McLean PJ, Hyman BT, Bogdahn U, Winkler J. Chaperon Proteine steuern die alpha-Synuclein Aggregation und Degradation. Akt Neurol 2007. [DOI: 10.1055/s-2007-987900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
21
|
Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol 2006; 111:101-8. [PMID: 16482476 DOI: 10.1007/s00401-005-0027-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2005] [Revised: 11/28/2005] [Accepted: 11/28/2005] [Indexed: 11/25/2022]
Abstract
Alpha-synuclein is a major constituent of Lewy bodies, the fibrillar aggregates that form within neurons in Parkinson's disease and dementia with Lewy bodies (DLB). Recent biochemical data show that alpha-synuclein accumulates in Parkinson's disease in a detergent insoluble form. We now examine the relationship between detergent insoluble alpha-synuclein and the presence of Lewy bodies, clinical measures of dementia and biochemical parameters in a series of individuals with DLB. We found that Triton X-100 insoluble alpha-synuclein enriched nearly twofold in the temporal cortex of patients with DLB compared to age-matched controls. By contrast the total amount of alpha-synuclein protein was unchanged. Surprisingly, the degree of Triton X-100 insoluble alpha-synuclein did not correlate with either the duration of illness or the number of Lewy bodies counted using stereological methods from an adjacent block of tissue. However, the Triton X-100 soluble fraction of alpha-synuclein did correlate strongly with the expression of several heat shock proteins (HSPs) in DLB but not control cases, suggesting a coordinated HSP response in DLB neocortex.
Collapse
Affiliation(s)
- J Klucken
- Department of Neurology, MassGeneral Institute for Neurodegenerative disease, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Klucken J, McLean PJ, Gomez-Tortosa E, Ingelsson M, Hyman BT. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res 2004; 28:1683-91. [PMID: 14584822 DOI: 10.1023/a:1026061021946] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders that share progressive dementia as the common major clinical symptom. Damages to memory-related brain structures are the likely pathological correlate, and in both illnesses deposition of amyloidogenic proteins are present mainly within these limbic structures. Amyloid-beta-positive plaques and phospho-tau-positive neurofibrillary tangles are the main feature of AD and alpha-synuclein-positive Lewy bodies and Lewy neurites are found in DLB. Interestingly the associated proteins also interfere with synaptic function and synaptic plasticity. Here, we propose that the same neuronal circuits are disturbed within the hippocampal formation in AD and DLB and that in both diseases the associated proteins might lead to changes in synaptic plasticity and function. Thus both classic neuropathological changes and cellular dysfunctions might contribute to the cognitive impairments in AD and DLB.
Collapse
Affiliation(s)
- J Klucken
- Alzheimer's Disease Research Laboratory, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | | | | | | | | |
Collapse
|
23
|
Klucken J, Shin Y, Mclean PJ, Hyman BT. Chaperone mediated degradation of aggregated alpha synuclein. Akt Neurol 2004. [DOI: 10.1055/s-2004-833268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
24
|
Langmann T, Porsch-Ozcürümez M, Unkelbach U, Klucken J, Schmitz G. Genomic organization and characterization of the promoter of the human ATP-binding cassette transporter-G1 (ABCG1) gene. Biochim Biophys Acta 2000; 1494:175-80. [PMID: 11072082 DOI: 10.1016/s0167-4781(00)00215-3] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The ATP-binding cassette transporter G1 (ABCG1) was recently identified as a regulator of macrophage cholesterol and phospholipid transport. This transporter together with ABCA1 belongs to a group of sterol-sensitive ABC proteins which are induced by lipid loading or specific oxysterols. We report here the genomic structure of ABCG1 along with the 5' flanking sequence using library screening and BLAST search analysis. The ABCG1 gene spans more than 70 kb and contains 15 exons. The exon size is between 30 and 1081 bp and the introns range in size from 137 bp to more than 45 kb. All exon-intron boundaries display the canonical GT/AG sequences. Using promoter-luciferase reporter assays in the myeloid cell lines THP-1 and RAW246.7 and the hepatoma cell line HepG2 we could demonstrate the functionality of the ABCG1 promoter and the minimal sequence requirements for gene expression. The TATA-less proximal promoter contains multiple Sp1 binding sites and a consensus sequence for sterol regulatory element binding protein.
Collapse
Affiliation(s)
- T Langmann
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042, Regensburg, Germany
| | | | | | | | | |
Collapse
|
25
|
Kaminski WE, Orsó E, Diederich W, Klucken J, Drobnik W, Schmitz G. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). Biochem Biophys Res Commun 2000; 273:532-8. [PMID: 10873640 DOI: 10.1006/bbrc.2000.2954] [Citation(s) in RCA: 116] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We report the identification of the full-length cDNA for a novel ATP-binding cassette (ABC) transporter from human macrophages. The mRNA is of 6.8 kb size and contains an open reading frame encoding a polypeptide of 2146 amino acids with a calculated molecular weight of 220 kDa. The predicted protein product is composed of two transmembrane domains and two nucleotide binding folds indicating that it pertains to the group of full-size ABC transporters. The novel transporter shows highest protein sequence homology with the recently cloned human cholesterol and phospholipid exporter ABCA1 (54%) and the human retinal transporter ABCR (49%), both members of the ABC transporter subfamily A. In accordance with the currently proposed classification, the novel transporter was designated ABCA7. ABCA7 mRNA was detected predominantly in myelo-lymphatic tissues with highest expression in peripheral leukocytes, thymus, spleen, and bone marrow. Expression of ABCA7 is induced during in vitro differentiation of human monocytes into macrophages. In macrophages, both the ABCA7 mRNA and protein expression are upregulated in the presence of modified low density lipoprotein and downregulated by HDL(3). Our results suggest a role for ABCA7 in macrophage transmembrane lipid transport.
Collapse
Affiliation(s)
- W E Kaminski
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, D-93042, Germany
| | | | | | | | | | | |
Collapse
|
26
|
Kaminski W, Klucken J, Schmitz G. ABCA7, A novel ABC transporter potentially involved in Macrophage Lipid Metabolism. Atherosclerosis 2000. [DOI: 10.1016/s0021-9150(00)81066-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G. The scavenger receptor CD136 is regulated by pro- and antiinflammtory mediators and by PPAR-γ activation. Atherosclerosis 2000. [DOI: 10.1016/s0021-9150(00)80906-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Schmitz G, Kaminski WE, Porsch-Ozcürümez M, Klucken J, Orsó E, Bodzioch M, Büchler C, Drobnik W. ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism? Pathobiology 2000; 67:236-40. [PMID: 10725792 DOI: 10.1159/000028100] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Activated lipid-laden macrophages in the vascular wall are key modulators of the inflammatory processes underlying atherosclerosis. We demonstrate here that the ATP-binding cassette (ABC) transporter ABCA1 is induced during differentiation of human monocytes into macrophages. ABCA1 has been implicated in macrophage interleukin-1beta secretion and apoptosis. Moreover, ABCA1 mRNA and protein levels are strongly upregulated by uptake of modified LDL and downregulated by HDL(3)-mediated lipid efflux in macrophages. Mutation analysis in patients with the classical Tangier disease (TD), a monogenetic disorder characterized by hypersplenism, macrophage accumulation and deposition of cholesteryl esters in the reticuloendothelial system, low plasma HDL and premature atherosclerosis, revealed deleterious mutations in their ABCA1 gene. The localization pattern of the mutations within the ABCA1 protein appears to determine the tropism for either the reticuloendothelial system, as seen in the classical TD phenotype, or the artery wall, as in the case of HDL deficiency in the absence of splenomegaly. In a comprehensive analysis of the expression and regulation of all currently known human ABC transporters, we identified additional cholesterol-responsive genes that are induced during monocyte differentiation into macrophages. Our results indicate a dual regulatory function for ABCA1 in macrophage lipid metabolism and inflammation.
Collapse
Affiliation(s)
- G Schmitz
- Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G. The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology 2000; 67:257-61. [PMID: 10725797 DOI: 10.1159/000028105] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
CD163 is a recently identified member of the scavenger receptor cysteine-rich superfamily expressed on peripheral blood monocytes and most tissue macrophages. We demonstrate that in vitro culture of human blood monocytes with recombinant M-CSF induces CD163 transcription. In contrast, dendritic differentiation in the presence of GM-CSF and IL-4 suppresses CD163 mRNA and protein levels. Because an important function of CD163 in inflammation has been suggested, we investigated the influence of pro- and anti-inflammatory stimuli on CD163 expression and found a significant suppression by lipoposaccharide and IFN-gamma, whereas IL-10 or dexamethasone strongly induced the expression of CD163. The induction of CD163 mRNA by dexamethasone is suggested to be mediated by several glucocorticoid receptor binding sites located in the proximal promoter region. In addition, this sequence contains potential binding sites for the transcription factors Sp1, C/EBPalpha, Ets-2, PU.1 and AP-1, which have been shown to play an important role in myeloid-specific gene expression. We also identified an L1-transposable element 1.4 kb upstream of the transcription start site that might influence the promoter activity. The function of CD163 may also depend on the use of different isoforms. Several variants of CD163 mRNA have been described that encode proteins with altered cytoplasmic or extracellular domains and thus may differ in their functional properties. We analyzed the genomic organization of the CD163 gene and could demonstrate that these isoforms result from alternative splicing. Further characterization of the isoforms may help to understand the complete function of CD163.
Collapse
MESH Headings
- Alternative Splicing
- Animals
- Antigens, CD
- Antigens, Differentiation, Myelomonocytic/genetics
- Antigens, Differentiation, Myelomonocytic/metabolism
- Cells, Cultured
- Cloning, Molecular
- Cytokines/pharmacology
- Dendritic Cells/metabolism
- Dexamethasone/pharmacology
- Flow Cytometry
- Humans
- In Situ Hybridization, Fluorescence
- Lipopolysaccharides/pharmacology
- Macrophages/metabolism
- Mice
- Monocytes/drug effects
- Monocytes/metabolism
- Promoter Regions, Genetic
- RNA, Messenger/metabolism
- Receptors, Cell Surface
Collapse
Affiliation(s)
- M Ritter
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
| | | | | | | | | | | |
Collapse
|
30
|
Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Ozcürümez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A 2000; 97:817-22. [PMID: 10639163 PMCID: PMC15414 DOI: 10.1073/pnas.97.2.817] [Citation(s) in RCA: 420] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Excessive uptake of atherogenic lipoproteins such as modified low-density lipoprotein complexes by vascular macrophages leads to foam cell formation, a critical step in atherogenesis. Cholesterol efflux mediated by high-density lipoproteins (HDL) constitutes a protective mechanism against macrophage lipid overloading. The molecular mechanisms underlying this reverse cholesterol transport process are currently not fully understood. To identify effector proteins that are involved in macrophage lipid uptake and release, we searched for genes that are regulated during lipid influx and efflux in human macrophages using a differential display approach. We report here that the ATP-binding cassette (ABC) transporter ABCG1 (ABC8) is induced in monocyte-derived macrophages during cholesterol influx mediated by acetylated low-density lipoprotein. Conversely, lipid efflux in cholesterol-laden macrophages, mediated by the cholesterol acceptor HDL(3), suppresses the expression of ABCG1. Immunocytochemical and flow cytometric analyses revealed that ABCG1 is expressed on the cell surface and in intracellular compartments of cholesterol-laden macrophages. Inhibition of ABCG1 protein expression using an antisense strategy resulted in reduced HDL(3)-dependent efflux of cholesterol and choline-phospholipids. In a comprehensive analysis of the expression and regulation of all currently known human ABC transporters, we identified an additional set of ABC genes whose expression is regulated by cholesterol uptake or HDL(3)-mediated lipid release, suggesting a potential function for these transporters in macrophage lipid homeostasis. Our results demonstrating a regulator function for ABCG1 in cholesterol and phospholipid transport define a biologic activity for ABC transporters in macrophages.
Collapse
Affiliation(s)
- J Klucken
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, 93042 Regensburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000; 67:97-103. [PMID: 10648003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
CD163, also referred to as M130, a member of the scavenger receptor cysteine-rich family (SRCR) is exclusively expressed on cells of the monocyte lineage. In freshly isolated monocytes the CD14bright CD16+ monocyte subset revealed the highest expression of CD163 among all monocyte subsets. CD163 mRNA and protein expression is up-regulated during macrophage colony-stimulating factor (M-CSF)-dependent phagocytic differentiation of human blood monocytes. In contrast, monocytic cells treated with GM-CSF and interleukin-4 (IL-4) for dendritic differentiation down-regulate this antigen. CD163 expression is also suppressed by proinflammatory mediators like lipopolysaccharide (LPS), interferon-gamma (IFN-gamma), and tumor necrosis factor alpha, whereas IL-6 and the antiinflammatory cytokine interleukin-10 (IL-10) strongly up-regulate CD163 mRNA in monocytes and macrophages. The effects of the immunosuppressants dexamethasone, cyclosporin A (CA), and cortisol differ in their capacity to influence CD163 mRNA levels. Our results demonstrate that CD163 expression in monocytes/macrophages is regulated by proinflammatory and antiinflammatory mediators. This expression pattern implies a functional role of CD 163 in the antiinflammatory response of monocytes.
Collapse
Affiliation(s)
- C Buechler
- Institut für Klinische Chemie und Laboratoriumsmedizin, Klinikum der Universität Regensburg, Germany
| | | | | | | | | | | |
Collapse
|
32
|
Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-51. [PMID: 10431237 DOI: 10.1038/11914] [Citation(s) in RCA: 1167] [Impact Index Per Article: 46.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Tangier disease (TD) is an autosomal recessive disorder of lipid metabolism. It is characterized by absence of plasma high-density lipoprotein (HDL) and deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes. Although low HDL cholesterol is associated with an increased risk for coronary artery disease, this condition is not consistently found in TD pedigrees. Metabolic studies in TD patients have revealed a rapid catabolism of HDL and its precursors. In contrast to normal mononuclear phagocytes (MNP), MNP from TD individuals degrade internalized HDL in unusual lysosomes, indicating a defect in cellular lipid metabolism. HDL-mediated cholesterol efflux and intracellular lipid trafficking and turnover are abnormal in TD fibroblasts, which have a reduced in vitro growth rate. The TD locus has been mapped to chromosome 9q31. Here we present evidence that TD is caused by mutations in ABC1, encoding a member of the ATP-binding cassette (ABC) transporter family, located on chromosome 9q22-31. We have analysed five kindreds with TD and identified seven different mutations, including three that are expected to impair the function of the gene product. The identification of ABC1 as the TD locus has implications for the understanding of cellular HDL metabolism and reverse cholesterol transport, and its association with premature cardiovascular disease.
Collapse
Affiliation(s)
- M Bodzioch
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999; 257:29-33. [PMID: 10092505 DOI: 10.1006/bbrc.1999.0406] [Citation(s) in RCA: 406] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
We have cloned the full-length cDNA for the human ATP binding cassette transporter 1 (hABC1). The 6603-bp open reading frame encodes a polypeptide of 2201 amino acids resulting in a deduced molecular weight of 220 kDa. The hABC1 cDNA is highly homologous (62%) to the human rim ABC transporter (ABCR). hABC1 is expressed in a variety of human tissues with highest expression levels found in placenta, liver, lung, adrenal glands, and fetal tissues. We demonstrate that the hABC1 expression is induced during differentiation of human monocytes into macrophages in vitro. In macrophages, both the hABC1 mRNA and protein expression are upregulated in the presence of acetylated low-density lipoprotein (AcLDL). The AcLDL-induced increase in hABC1 expression is reversed by cholesterol depletion mediated by the addition of high-density lipoprotein (HDL3). Our data, demonstrating sterol-dependent regulation of hABC1 in human monocytes/macrophages, suggest a novel role for this transporter molecule in membrane lipid transport.
Collapse
MESH Headings
- ATP Binding Cassette Transporter 1
- ATP-Binding Cassette Transporters/chemistry
- ATP-Binding Cassette Transporters/genetics
- ATP-Binding Cassette Transporters/metabolism
- Amino Acid Sequence
- Blotting, Northern
- Blotting, Western
- Cell Differentiation/drug effects
- Cells, Cultured
- Cloning, Molecular
- DNA, Complementary/genetics
- Gene Expression Regulation/drug effects
- Glycoproteins/chemistry
- Glycoproteins/genetics
- Glycoproteins/metabolism
- Humans
- Lipoproteins, HDL/metabolism
- Lipoproteins, HDL/pharmacology
- Lipoproteins, LDL/antagonists & inhibitors
- Lipoproteins, LDL/metabolism
- Lipoproteins, LDL/pharmacology
- Macrophage Colony-Stimulating Factor/pharmacology
- Macrophages/drug effects
- Macrophages/metabolism
- Molecular Sequence Data
- Molecular Weight
- Monocytes/drug effects
- Monocytes/metabolism
- Open Reading Frames/genetics
- RNA, Messenger/metabolism
- Sequence Homology, Amino Acid
- Sterols/metabolism
Collapse
Affiliation(s)
- T Langmann
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, 93042, Germany
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Integrins are in physical association and functional cooperation with other membrane proteins that include receptors with scavenger functions, glycosyl-phosphatidylinositol-linked receptors, the family of integrin associated multimembrane spanning signalling proteins and possibly other less characterized proteins with a coupling or signalling function. Monocyte adhesion, migration and differentiation to phagocytically active scavenger cells are directly coupled processes, involving integrins as common transducers for a panel of integrin-linked specific receptors, which assemble a master cluster to coordinate adhesion, migration, scavenging and associated metabolic pathways of the lysosomal and secretory route, and also processes involved in host response. As macrophages represent highly heterogeneous cells that have major phenotypical and functional differences associated with specific patterns of integrin expression, the functional cooperation of integrins with scavenger receptors has to be related to specialized subsets of monocytes and macrophages as well as to ligand specific effects which mediate receptor coupling.
Collapse
Affiliation(s)
- G Schmitz
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany.
| | | | | | | |
Collapse
|
35
|
Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kindermann W, Schmitz G. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16:1437-47. [PMID: 8977447 DOI: 10.1161/01.atv.16.12.1437] [Citation(s) in RCA: 128] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Mononuclear phagocytes play a major role in the development of vascular lesions in atherogenesis. The goal of our study was to characterize circulating blood monocyte subpopulations as potential cellular markers of systemic immunological abnormalities in hypercholesterolemia. In normal subjects, three-parameter immunophenotyping of whole blood revealed that 61.3 +/- 6.0% of monocytes showed "bright" expression of the lipopolysaccharide receptor (LPSR: CD14) and Fc gamma receptor I (RI: CD64) without expression of Fc gamma-RIII (CD16). Other monocyte subsets (populations 2, 3, 4, and 5) were characterized by the simultaneous expression of both Fc gamma-R's (25.6 +/- 5.0%), isolated expression of Fc gamma-RIII (9.4 +/- 1.7%), or high expression of CD33 (3.7 +/- 1.1%) with only dim expression of CD14, respectively. The smallest subset of monocytes (population 5: 2.1 +/- 0.8%) differed from the predominant population of CD14brightCD64+CD16- monocytes by additional expression of neural cell adhesion molecule (N-CAM: CD56). In a group of hypercholesterolemic patients (n = 19), high density lipoprotein cholesterol levels were negatively correlated to the population size of CD64-CD16+ monocytes. In both healthy subjects (n = 55) and hypercholesterolemic patients, the rare apolipoprotein E3/E4 and E4/E4 phenotypes were associated with a tendency toward a larger population of CD64-CD16+ monocytes. Expression of the variant activation antigen CD45RA by peripheral blood mononuclear phagocytes showed a positive correlation to plasma levels of the atherogenic lipoproteins low density lipoprotein and lipoprotein(a). These data suggest that systemic abnormalities in mononuclear phagocyte subpopulations may play a role in the pathogenesis of atherosclerosis.
Collapse
Affiliation(s)
- G Rothe
- Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany
| | | | | | | | | | | | | |
Collapse
|